OpenLB
Open Library of Bioscience
Advanced Search

Journal Of Thoracic Oncology

Journal Information
Journal Abbr. J Thorac Oncol
Web of Sciences Category
Oncology Respiratory System
Print ISSN 1556-0864
E-ISSN 1556-1380
NLM Catelog ID 101274235
Scopus Source ID 6400153137
Country UNITED STATES
Language English
Publisher Elsevier Science Inc
Publisher Address Ste 800, 230 Park Ave, New York, Usa, Ny, 10169

Related Publications

Found 5,954 results

Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 Non-Small Cell Lung Cancer: Primary Results from SQUAT trial (WJOG 12119L).
Akira Hamada, Junichi Soh, Akito Hata, Kiyoshi Nakamatsu, Mototsugu Shimokawa, Yasushi Yatabe, Jun Suzuki, Masahiro Tsuboi, Hidehito Horinouchi, Yuichi Sakairi, Masayuki Tanahashi, Shinichi Toyooka, Morihito Okada, Natusmi Matsuura, Hisayuki Shigematsu, Yasumasa Nishimura, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Tetsuya Mitsudomi
J Thorac Oncol. Apr 09, 2025.: Print-Electronic
Source:PubMed
PMID: 40216327 doi:10.1016/j.jtho.2025.03.051
Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial.
Binghao Zhao, Huanzhang Li, Jiaming Wu, Wenbin Ma
J Thorac Oncol. 01, 2023.18(1):e1-e2 Print
Source:PubMed
PMID: 36543435 doi:10.1016/j.jtho.2022.09.002
A Perspective on the MARS2 Trial.
Eric Lim, Isabelle Opitz, Gavitt Woodard, Raphael Bueno, Marc de Perrot, Raja Flores, Ritu Gill, David Jablons, Harvey Pass
J Thorac Oncol. Jan 08, 2025.: Print-Electronic
Source:PubMed
PMID: 39772349 doi:10.1016/j.jtho.2024.12.014
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03.
Afshin Dowlati, Anne C Chiang, Andrés Cervantes, Sunil Babu, Erika Hamilton, Shu Fen Wong, Andrea Tazbirkova, Ivana Gabriela Sullivan, Cédric van Marcke, Antoine Italiano, Jilpa Patel, Sabeen Mekan, Tia Wu, Saiama N Waqar
J Thorac Oncol. Jan 02, 2025.: Print-Electronic
Source:PubMed
PMID: 39755168 doi:10.1016/j.jtho.2024.12.028
Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E Marmarelis, Yuichiro Ohe, Reyes Bernabe Caro, Dong-Wan Kim, Jong-Seok Lee, Sophie Cousin, Eiki Ichihara, Yongsheng Li, Luis Paz-Ares, Akira Ono, Rachel E Sanborn, Naohiro Watanabe, Maria Jose de Miguel, Carole Helissey, Catherine A Shu, Alexander I Spira, Pascale Tomasini, James Chih-Hsin Yang, Yiping Zhang, Enriqueta Felip, Frank Griesinger, Saiama N Waqar, Antonio Calles, Joel W Neal, Christina S Baik, Pasi A Jänne, S Martin Shreeve, Joshua C Curtin, Bharvin Patel, Michael Gormley, Xuesong Lyu, Jun Chen, Pei-Ling Chu, Janine Mahoney, Leonardo Trani, Joshua M Bauml, Meena Thayu, Roland E Knoblauch, Byoung Chul Cho
J Thorac Oncol. Jan 02, 2025.: Print-Electronic
Source:PubMed
PMID: 39755170 doi:10.1016/j.jtho.2024.12.029
A Prospective Phase II Trial of First-line Osimertinib for Patients with EGFR Mutation-positive Non-small Cell Lung Cancer and Poor Performance Status (OPEN/TORG2040).
Tomoya Fukui, Nobuaki Mamesaya, Toshiaki Takahashi, Kazuma Kishi, Takahiro Yoshizawa, Takaaki Tokito, Koichi Azuma, Kei Morikawa, Satoshi Igawa, Yusuke Okuma, Yuta Yamanaka, Shinobu Hosokawa, Takashi Kasai, Ken Masubuchi, Shinji Nakamichi, Masaharu Aga, Jiichiro Sasaki, Akiko Kada, Akiko M Saito, Katsuhiko Naoki, Hiroaki Okamoto, Thoracic Oncology Research Group (TORG)
J Thorac Oncol. Jan 02, 2025.: Print-Electronic
Source:PubMed
PMID: 39755169 doi:10.1016/j.jtho.2024.12.027
Brief Report: Evaluating Early-Stage Lung Cancer Survival Patterns in Patients at the Upper Age Limit for Lung Cancer Screening.
Matthew T Warkentin, Martin C Tammemägi, Erik Vakil, Eric L R Bedard, Winson Y Cheung, Darren R Brenner, Alain Tremblay
J Thorac Oncol. Dec 30, 2024.: Print-Electronic
Source:PubMed
PMID: 39743140 doi:10.1016/j.jtho.2024.12.025
In situ detection of PD1-PD-L1 interactions as a functional predictor for response to immune checkpoint inhibition in NSCLC.
Amanda Lindberg, Lars Muhl, Hui Yu, Louise Hellberg, Rebecca Artursson, Jakob Friedrich, Max Backman, Neda Hekmati, Johanna Mattsson, Cecilia Lindskog, Hans Brunnström, Johan Botling, Artur Mezheyeuski, Erika Broström, Miklos Gulyas, Klas Kärre, Johan Isaksson, Patrick Micke, Carina Strell
J Thorac Oncol. Dec 30, 2024.: Print-Electronic
Source:PubMed
PMID: 39743139 doi:10.1016/j.jtho.2024.12.026
Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA).
Jii Bum Lee, Su-Jin Choi, Hyo Sup Shim, Byung Jo Park, Chang Young Lee, Sumedha Sudhaman, Sharlene Velichko, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
J Thorac Oncol. Dec 26, 2024.: Print-Electronic
Source:PubMed
PMID: 39732365 doi:10.1016/j.jtho.2024.12.023
AYVM to AYMM transition on HER2 exon 20 insertion induces TKI resistance in NSCLC.
Shiqi Mao, Xinyu Liu, Lin Wang, Yan Wang, Shuo Yang, Tao Jiang, Xingya Li, Qiming Wang, Xuefei Li, Fengying Wu, Guanghui Gao, Xiaoxia Chen, Chunyan Wu, Wei Zhang, Jiao Zhang, Xiang Lin, Xiaoyu Zhu, Baobin Li, Fei Li, Caicun Zhou, Shengxiang Ren
J Thorac Oncol. Dec 24, 2024.: Print-Electronic
Source:PubMed
PMID: 39725168 doi:10.1016/j.jtho.2024.12.022